D R Howard
Overview
Explore the profile of D R Howard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Howard D, Munir T, McParland L, Rawstron A, Milligan D, Schuh A, et al.
Leukemia
. 2017 Mar;
31(11):2416-2425.
PMID: 28336937
ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). The...
2.
Munir T, Howard D, McParland L, Pocock C, Rawstron A, Hockaday A, et al.
Leukemia
. 2017 Feb;
31(10):2085-2093.
PMID: 28216660
ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence...
3.
Walleser L, Howard D, Sandheinrich M, Gaikowski M, Amberg J
J Fish Biol
. 2014 Aug;
85(5):1777-84.
PMID: 25141916
To better understand potential diet overlap among exotic Asian species of carp and native species of filter-feeding fishes of the upper Mississippi River system, microscopy was used to document morphological...
4.
Chaney W, Howard D, Pollard J, Sallustio S, Stanley P
Methods Mol Biol
. 2011 Mar;
4:363-70.
PMID: 21424646
Many techniques have been developed to transfect mammalian cells with DNA (1-2). The most commonly used method is to expose cells to a coprecipitate of DNA and calcium phosphate (3)....
5.
Coppes M, Yanofsky R, Pritchard S, Leclerc J, Howard D, Perrotta M, et al.
J Pediatr Hematol Oncol
. 1999 Aug;
21(4):274-83.
PMID: 10445889
Purpose: The safety, antiemetic efficacy, and pharmacokinetics of single oral doses of dolasetron, a new highly selective 5-HT3 receptor antagonist, were evaluated in children with cancer undergoing treatment with moderately...
6.
Coppes M, Lau R, Ingram L, Wiernikowski J, Grant R, Howard D, et al.
Med Pediatr Oncol
. 1999 Jul;
33(2):99-105.
PMID: 10398184
Background: Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure: An open-label dose-escalation study was conducted to assess the appropriate intravenous dose of dolasetron...
7.
Frequent loss of heterozygosity for chromosome 10 in uterine leiomyosarcoma in contrast to leiomyoma
Quade B, Pinto A, Howard D, Peters 3rd W, Crum C
Am J Pathol
. 1999 Mar;
154(3):945-50.
PMID: 10079273
Distinction of malignant uterine leiomyosarcomas from benign leiomyomas by morphological criteria is not always possible. Leiomyosarcomas typically have complex cytogenetic abnormalities; in contrast, leiomyomas have simple or no cytogenetic abnormalities....
8.
Neau S, Howard M, Claudius J, Howard D
Int J Pharm
. 1999 Mar;
179(1):97-105.
PMID: 10053206
Release data from ethylcellulose (EC) matrix tablets was analyzed to determine which release equation provides the best fit to the data and to observe the effect of drug solubility on...
9.
Grunder G, Yokoi F, Offord S, Ravert H, Dannals R, Salzmann J, et al.
Neuropsychopharmacology
. 1997 Sep;
17(3):175-85.
PMID: 9272484
MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using...
10.
Florence L, Howard D, Chapman P, Lieberman J, Perkinson D, Marks W
Transplant Proc
. 1997 Feb;
29(1-2):313-4.
PMID: 9123016
No abstract available.